Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992911 | 0.89 | ACACB (0.37) | SLC7A5ALDH1A1TSHR | |
| SCHEMBL1401065 | 0.83 | CETP (0.39) | PSMB5SLC7A5CETPKDM1AMAOB | |
| SCHEMBL7638289 | 0.81 | SLC7A5 (0.40) | PSMB5SLC7A5CETPKDM1AMAOB | |
| SCHEMBL4990305 | 0.78 | SMN1; SMN2 (0.39) | ALDH1A1TSHRPOLBLMNA | |
| SCHEMBL1401061 | 0.77 | SLC7A5 (0.39) | PSMB5SLC7A5KDM1AMAOBRCOR1 | |
| SCHEMBL4990862 | 0.76 | MMP13 (0.37) | ALDH1A1LMNA | |
| SCHEMBL4992838 | 0.76 | SLC7A5 (0.36) | PSMB5SLC7A5CETPKDM1AMAOB | |
| SCHEMBL26690016 | 0.70 | SLC7A5 (0.59) | PSMB5SLC7A5FFAR1ALDH1A1TSHR | |
| SCHEMBL915374 | 0.68 | LOXL2 (0.51) | SLC7A5ALDH1A1TSHRKDM4E | |
| SCHEMBL4080225 | 0.68 | AKR1B1 (0.52) | SLC7A5FFAR1ALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005027931-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AN EP2 OR EP4 SELECTIVE AGONIST | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6747054-B2 | FOR THERAPY OF LOW BONE MASS, PARTICULARLY OSTEOPOROSIS, FRAILTY, AN OSTEOPOROTIC FRACTURE, A BONE DEFECT, CHILDHOOD IDIOPATHIC BONE LOSS, ALVEOLAR BONE LOSS, MANDIBULAR BONE LOSS, BONE FRACTURE, OSTEOTOMY | PFIZER INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | CAMERON KIMBERLY O (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003077910-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1339678-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | PTGER4, PTGER1, PTGER2 | PSMB5 1671/4885SLC7A5 2159/4885CETP 1762/4885 |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PSMB5 540/4885SLC7A5 3685/4885CETP 3159/4885 |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PSMB5 528/4885SLC7A5 3675/4885CETP 3231/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PSMB5 528/4885SLC7A5 3675/4885CETP 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.